Tuesday, 20 April 2021 01:45 GMT

Conversion Labs to Present at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 18, 2021 Nasdaq:CVLB


( MENAFN - GlobeNewsWire - Nasdaq N )EW YORK, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a leading direct-to-patient telehealth company, has been invited to present at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference being held on February 17-19, 2021.

Conversion Labs CEO Justin Schreiber is scheduled to present in a fireside chat on Thursday, February 18 at 1:00 p.m. Eastern time. He will be joined by the company's chief business officer, Corey Deutsch, for the presentation and virtual one-on-one meetings with institutional analysts and investors throughout the conference.

The presentation will be webcast live and available for replay here and via the investor relations section of the company's website at ConversionLabs.com .

Management will discuss the company's recently announced plans to change its name to LifeMD on February 22. The name change will be followed by the official launch of its subscription-based primary care and concierge services designed to positively transform all aspects of a patient's healthcare. LifeMD's mobile-first interface will be powered by the company's proprietary Veritas MD digital health platform, providing a seamless integration between doctors, patients, medical information and pharmacy.

Management will also discuss the company's recently reported preliminary results for 2020, with revenue up 205% to $38.0 million. The record month of December ended the year at an annualized revenue run-rate of more than $60 million. Annual recurring revenue (ARR) generated by subscriptions is expected to total $26.0 million at yearend 2020, up 525% year-over-year.

Register for the conference here . To schedule a one-on-one meeting with the company, please contact your BTIG representative. To learn more about Conversion Labs, contact Ron Both of CMA at (949) 432-7557 or submit your request here .

About BTIG
BTIG is a global financial services firm specializing in institutional trading, investment banking, research and related brokerage services. With an extensive global footprint and more than 650 employees, BTIG, LLC and its affiliates operate out of 18 cities throughout the U.S., and in Europe, Asia and Australia. BTIG offers execution, expertise and insights for equities, equity derivatives, ETFs and fixed income, currency and commodities (futures, commodities, foreign exchange, interest rates, credit, and convertible and preferred securities). The firm's core capabilities include global execution, portfolio, electronic and outsource trading, transition management, investment banking, prime brokerage, capital introduction, corporate access, research and strategy, commission management and more. To learn more about BTIG, visit  .

About Conversion Labs
Conversion Labs, Inc. is a leading telehealth company offering a full portfolio of direct-to-patient products and services. The company combines virtual medical treatment with prescription medications and unique over-the-counter products. Its network of licensed physicians offers telemedicine services and direct-to-consumer pharmacy to consumers across the U.S. To learn more, visit Conversionlabs.com .

Important Cautions Regarding Forward-Looking Statements
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things our plans, strategies and prospects -- both business and financial. Although we believe that our plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot assure you that we will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Many of the forward-looking statements contained in this news release may be identified by the use of forward-looking words such as "believe," "expect," "anticipate," "should," "planned," "will," "may," "intend," "estimated," and "potential," among others. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include market conditions and those set forth in reports or documents that we file from time to time with the United States Securities and Exchange Commission. All forward-looking statements attributable to Conversion Labs, Inc. or a person acting on its behalf are expressly qualified in their entirety by this cautionary language.

LifeMD™, Veritas MD™, Shapiro MD™, Rex MD™ and Nava MD™ are trademarks of Conversion Labs. All other trademarks are the property of their respective owners.

Company Contact
Conversion Labs
Email Contact

Media and Investor Relations Contact
Ron Both or Grant Stude
CMA Investor Relations
Tel (949) 432-7566
Email Contact


MENAFN17022021004107003653ID1101616970


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.